Glaukos Corporation (GKOS)
| Market Cap | 2.41B |
| Revenue (ttm) | 294.01M |
| Net Income (ttm) | -38.37M |
| Shares Out | 46.89M |
| EPS (ttm) | -0.84 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 482,345 |
| Open | 53.01 |
| Previous Close | 53.20 |
| Day's Range | 50.68 - 53.53 |
| 52-Week Range | 39.35 - 99.00 |
| Beta | 1.67 |
| Analysts | Hold |
| Price Target | 55.75 (+8.5%) |
| Earnings Date | n/a |
About GKOS
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is des...
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for Glaukos stock is "Hold." The 12-month stock price forecast is 55.75, which is an increase of 8.51% from the latest price.
News
Glaukos' iDose TR Shows Sustained Reduction In Ocular Pressure, Favorable Safety Profile
Ophthalmic medical company Glaukos Corporation (NYSE: GKOS) announced data from the Phase 2b trial of iDose TR, a sustained-release travoprost implant. The data showed sustained and substantial reductio...
Glaukos' iDose® TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 36 Months in Phase 2b Study
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...
Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Dry Eye Disease
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...
Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Presbyopia
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...
Glaukos Announces FDA 510(k) Clearance of iPRIME™
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...
Here's Why You Should Hold on to Glaukos (GKOS) Stock Now
Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and solid performing iStent technology.
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...
Glaukos Announces Retirement of William J. Link, Ph.D.
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...
Glaukos Announces Participation in Upcoming Investor Conferences
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 American Academy of Ophthalmology Annual M...
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...
Glaukos (GKOS) Gains 3.6% Despite Reporting a Loss in Q3
Despite reporting third-quarter loss, Glaukos' (GKOS) results reflect a significant rise in revenues.
Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates
Glaukos (GKOS) delivered earnings and revenue surprises of 17.39% and 3.73%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Glaukos Corporation Announces Third Quarter 2021 Financial Results
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...
Why Glaukos Stock Is Soaring Today
CMS' final payment rates for 2022 spurred an analyst upgrade for Glaukos.
Why Are Glaukos Shares Rallying Today?
Glaukos Corporation (NYSE: GKOS) shares have gained as investors cheer the final physician payment rates and outpatient facility fees issued by the Centers for Medicare & Medicaid Services (CMS) for 202...
Analysts Estimate Glaukos (GKOS) to Report a Decline in Earnings: What to Look Out for
Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaukos Corporation to Release Third Quarter 2021 Financial Results after Market Close on November 4
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 European Society of Cataract and Refractiv...
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...
Glaukos Announces Licensing Agreement with Attillaps Holdings, Inc.
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...
Ivantis To Pay $60M In Patent Litigation Settlement With Glaukos
Glaukos Corp (NYSE:GKOS) has settled a patent infringement lawsuit with Ivantis Inc. The lawsuit was initiated by Glaukos in 2018 in the U.S. District Court for the Central District of California, South...
Glaukos Announces Settlement of Patent Litigation with Ivantis, Inc.
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...
Glaukos (GKOS) Announces PMA Submission, Boosts iStent Platform
Glaukos (GKOS) submits PMA application to the FDA, which can enhance the company's deep portfolio of novel glaucoma surgical devices and sustained pharmaceuticals.
Glaukos Files Pre-Market Application For Intraocular Pressure Device
Glaukos Corp (NYSE: GKOS) has submitted a supplemental premarket approval (PMA) application to the FDA for its iStent infinite Trabecular Micro-Bypass System. Related Content: William Blair Downgrades...
Glaukos Announces Submission of Supplemental Pre-Market Approval Application for iStent infinite™
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...
Glaukos Announces Participation in the Wells Fargo Healthcare Conference
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal dis...